WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
US border arrests fall in April, bucking usual spring increase as Mexico steps up enforcementMarvel selects a final title for WandaVision spinFuture of Texas' migrantThe Fortune Hotel viewers spot contestant who has already been on another reality TV showFIFA members to vote on the host of the 2027 Women's World CupWhite Sox acquire outfielder Corey Julks from Astros, recall outfielder Dominic FletcherMarvel selects a final title for WandaVision spinAmanda Bynes flaunts tummy in selfie as her former All That coBarron Trump won't be serving as a Florida delegate to the RNCWhy the speech by Kansas City Chiefs kicker was embraced at Benedictine College's commencement